SAN DIEGO, Oct. 16, 2017 /PRNewswire/ Prometheus Laboratories Inc. introduces the FIBROSpect® NASH test—a new tool to help
healthcare providers stratify nonalcoholic steatohepatitis (NASH) patients by risk, based on the severity of their liver fibrosis. NASH is a
potentially serious condition that is related to the more common and less severe nonalcoholic fatty liver disease (NAFLD). It is estimated
that one third of the U.S. adult population may have NAFLD with approximately 25 percent of those progressing to NASH. As the
incidence of these conditions grows, there is a critical need for noninvasive testing that measures the degree of fibrosis. Liver biopsy, an
invasive procedure, is the current gold standard for diagnosing and staging liver fibrosis.
Advanced stages of liver fibrosis have been proven to be the most significant independent risk factor for mortality in NASH patients.
FIBROSpect NASH differentiates between mild and advanced liver fibrosis stages to help healthcare providers stratify the risk of their
NASH patients and manage them accordingly.
"The new FIBROSpect NASH serum test overcomes some of the limitations of current invasive and noninvasive liver assessment
methods by pairing expertdeveloped proprietary algorithms with biomarkers that are clinically relevant to the development of liver
fibrosis specifically in NASH patients," said Warren Cresswell, General Manager and Head of Diagnostics at Prometheus Laboratories
Inc. "This is part of our new generation of diagnostic liver tests, based on scientific innovation and a strong investment, that anticipate
and meet the changing needs of healthcare providers in the growing liver health category."
"As more effective therapies become available to treat NASH patients, having noninvasive blood tests to assess the severity of the
patient's fibrosis stage will allow us to better stratify their risk and select the most appropriate course of action accordingly," said Manal
Abdelmalek, M.D., Associate Professor at the Duke University School of Medicine.
The FIBROSpect NASH test was developed and clinically validated with wellcharacterized and biopsyconfirmed NASH patients. The
clinical validation data is being presented at the 2017 American Association for the Study of Liver Diseases (AASLD) meeting, October
2024, in Washington, D.C.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical
and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the
principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is expanding product development to
oncology testing. The company complements its proprietary diagnostic testing services with therapeutic products. By integrating
therapeutics and diagnostics, Prometheus provides physicians with more targeted solutions to optimize care for their patients.
Prometheus became part of Nestlé Health Science in 2011. For more information about Prometheus, please visit
About Nestlé Health Science
Nestlé Health Science, a whollyowned subsidiary of Nestlé, is a healthscience company engaged in advancing the role of nutritional
therapy to change the course of health for consumers, patients, and its partners in healthcare. Nestlé Health Science's portfolio of
nutrition solutions, diagnostics, devices, and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and
acute care, obesity care, healthy aging, and gastrointestinal and brain health. Through investing in innovation and leveraging leadingedge
science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value, and quality of
life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne),
Switzerland. For more information, please visit: www.nestlehealthscience.com.
PROMETHEUS, the Link Design, For the person in every patient, and Monitr are trademarks or registered trademarks of Société des
Produits Nestlé S.A. Vevey, Switzerland.
Contact for the media:
Geri VenaShores, Head of Marketing